November 20, 2019
Terumo Acquires Aortica Corporation to Further Bolster Its Vascular Graft Portfolio
November 20, 2019—Terumo Corporation announced the acquisition of Aortica Corporation, which developed the AortaFit automated case planning software to match fenestrations on an endograft with unique locations for each of a patient's branch arteries during fenestrated endovascular aneurysm repair (FEVAR) cases. According to the company, AortaFit is intended to improve graft anchoring while minimizing the potential for endoleaks and migration that may result from the endovascular treatment of complex abdominal aortic aneurysms (AAAs).
AortaFit is being evaluated in an FDA-approved, physician-sponsored, investigational device exemption (IDE) study. Initial results for the first 30 patients undergoing FEVAR that was planned and performed using AortaFit have shown a 100% success rate, including 16 patients who were treated with the Treo AAA stent graft (Terumo Aortic).
The IDE study is led by Benjamin Starnes, MD, Chief of Vascular Surgery at the University of Washington in Seattle, Washington.
“Although several endografts are being studied under our protocol, the Treo abdominal aortic endograft has become our platform of choice because of its deliverability, conformability and graft design conducive to creating fenestrations,” said Dr. Starnes in the company’s announcement. “Treo is most likely to allow strut-free fenestrations in our series.”
Earlier this year, Endovascular Today interviewed Dr. Starnes about the AortaFit software, including how it works, potential applications, and details of the IDE study.
Terumo's announcement also highlighted its development of the BoulEVARd balloon-expandable covered stent graft that is specifically designed for use in FEVAR to enable reliable engagement into the main body graft while improving conformability to the native artery. The company explained that it plans to leverage the AortaFit system and the BoulEVARd covered stent graft with its Treo AAA system to transform how vascular disease management is performed for this challenging patient population.
The acquisition transaction is expected to close within 2019 and be funded through cash on hand. Terumo says it will continue the development of the Aortica’s products with plans to launch them in the United States, Europe, Japan, and other regions.